Shared instrumentation represents a institute-wide resource set up with modular locations to serve each of the CCSG Programs. Modular resources are housed in the Grace Cancer Drug Center (Therapeutics), Cell and Virus (Cancer Genetics and Mouse Molecular Genetics), and the Cancer Cell Center (Immunology). Mot of the equipment included within this resource is represented by those items common to most types of biomedical research. There are several objectives in maintaining shared instrumentation. Centralized support of this resource ensures continuous access to equipment commonly used by a variety of investigators conducting peer reviewed research and to allow access to those investigators applying for such support. Centralized equipment ensures maximum utilization and therefore cost efficiency of research dollars. Equipment included in the shared instrumentation resource is generally lumped together for service contract agreements. The inclusion of multiple pieces of equipment on the same service contract allow for discounted rates, stability of service contract agreements and minimization of disrupts due to equipment breakdown. Shared instrumentation also increases the availability of high-end equipment (e.g., ultracentrifuges, densitometers, imaging equipment) for which support by traditional individual investigator type funding (e.g., RO1 type support) is difficult to obtain. The shared instrumentation resource, in addition to allowing investigators to have access to a reliable facility for conducting a multitude of essential but conventional type studies, but also can allow investigators to take advantage of newly developed technology that requires equipment not generally supported by individual investigator awards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-25
Application #
6324616
Study Section
Project Start
2000-06-28
Project End
2001-04-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Leonova, Katerina; Safina, Alfiya; Nesher, Elimelech et al. (2018) TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. Elife 7:
Tubbs, Anthony; Sridharan, Sriram; van Wietmarschen, Niek et al. (2018) Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork Collapse. Cell 174:1127-1142.e19
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33

Showing the most recent 10 out of 1555 publications